Strategic Investment Overview: Shilpa Medicare's 30.4% Acquisition in Gate2Brain

Executive Summary Shilpa Medicare Ltd., via its wholly-owned subsidiary Shilpa Biocare Pvt. Ltd., has announced a €7 million strategic investment to acquire a 30.4% equity stake in Spain-based biotechnology firm Gate2Brain. This transaction marks Shilpa’s fourth strategic equity partnership, deliberately expanding its portfolio into high-value central nervous system (CNS) therapies and rare oncology assets Transaction Structure The €7 million transaction is efficiently structured to leverage Shilpa's existing operational strengths: Cash Infusion: €0.5 million. Equity-for-Services: €5.5 million, issued in exchange for Shilpa’s contract manufacturing and regulatory expertise. Development Capital: €1.0 million dedicated to advancing Gate2Brain’s lead oncology program. Strategic Role & Operational Synergies Under this agreement, Shilpa Biocare secures long-term commercialization exposure and will act as the exclusive contract manufacturing, chemistry-manufacturing-controls (CMC), and regulatory partner for Gate2Brain's lead candidate Core Technology & Pipeline (G2B-002) Gate2Brain is pioneering the MiniAp4 peptide-shuttle technology, a proprietary platform designed to solve the longstanding challenge of transporting therapeutics across the blood-brain barrier (BBB) Lead Asset (G2B-002): Utilizes the peptide shuttle to deliver SN-38, a potent anti-cancer compound, directly into the brain. It targets highly aggressive, rare cancers with limited treatment options, specifically diffuse intrinsic pontine glioma (DIPG) and pediatric glioblastoma Regulatory Advantage: G2B-002 has secured Orphan Drug Designation from both the US FDA and the European Medicines Agency (EMA), de-risking its pathway and offering future market exclusivity Forward Timeline: Clinical batch production is slated for 2027, with first-in-human clinical trials targeted for FY28.